Recall of ibrutinib and issues with therapeutic approval

BMJ Oncol. 2024 Aug 7;3(1):e000418. doi: 10.1136/bmjonc-2024-000418. eCollection 2024.

Authors

Colton Lipfert¹, Myung Sun Kim², Alyson Haslam³, Vinay K Prasad³

Affiliations

¹ Columbia University, Manhattan, New York, USA.
² Compass Oncology, Portland, Oregon, USA.
³ Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

No abstract available

Keywords: Lymphoma; Pharmacotherapy.

Publication types

Editorial